Cargando…

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study

Sickle cell disease (SCD) is an inherited red blood cell disease that results in a multitude of medical complications, including an increased risk of invasive disease caused by encapsulated bacteria, such as Streptococcus pneumoniae. Pneumococcal vaccines have contributed to a significant reduction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quinn, Charles T., Wiedmann, Richard T., Jarovsky, Daniel, Lopez-Medina, Eduardo, Rodriguez, Hilze M., Papa, Melanie, Boggio, Gordana, Shou, Qiong, Dagan, Ron, Richmond, Peter, Feemster, Kristen, McFetridge, Richard, Tamms, Gretchen, Lupinacci, Robert, Musey, Luwy, Bickham, Kara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979710/ https://www.ncbi.nlm.nih.gov/pubmed/36383730 http://dx.doi.org/10.1182/bloodadvances.2022008037

Ejemplares similares

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)
por: Banniettis, Natalie, et al.
Publicado: (2021)

1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
por: Bili, Adroniki, et al.
Publicado: (2021)

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies
por: Chapman, Timothy J., et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
por: Hammitt, Laura L, et al.
Publicado: (2021)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
por: Mohapi, Lerato, et al.
Publicado: (2022)

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
por: Hammitt, Laura, et al.
Publicado: (2021)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

P07 A Phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114 pneumococcal vaccine in haematopoietic cell transplant recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)
por: Wilck, M., et al.
Publicado: (2022)

IAU Colloquium No. 114
por: Wegner, Gary
Publicado: (1989)

Cavity for 114.6 MHz
por: Croizat, M, et al.
Publicado: (1984)

114th LHCC Meeting
Publicado: (2013)

114th SPSC Meeting
Publicado: (2014)

Conditioning of the 114 MHz cavity
por: Hohbach, R
Publicado: (1990)

114 VLPs and particle vaccines
por: Buonaguro, Luigi
Publicado: (2014)

Subject index for volume 114()
Publicado: (1981)

Health Tract, No. 114: Fireplaces
Publicado: (1862)

Gravitational lensing by the rich cluster AC114
por: Smail, Ian, et al.
Publicado: (1994)

Requiem ; Psalm 114 ; Psalm 112
por: Bruckner, Anton, 1824-1896
Publicado: (1987)

Reforma al Artículo 114 Constitucional
por: Malpica García, Claudia
Publicado: (1997)

Fibrosis. Ciba Foundation Symposium 114
por: Basson, Craig Todd
Publicado: (1986)

New elements: approaching Z=114
por: Hofmann, S
Publicado: (1998)

Beam Decay Rate Run 114
por: CERN. Geneva. Intersecting Storage Ring Division
Publicado: (1971)

Rhabdomyolysis in 114 patients with acute poisonings
por: Mousavi, Seyed Reza, et al.
Publicado: (2015)

Abstracts des 114. Internistenkongresses 2008
Publicado: (2008)

Health Tract, No. 114: Fire-Places
Publicado: (1865)

On the adsorption and reactivity of element 114, flerovium
por: Yakushev, A., et al.
Publicado: (2022)

Impaired transmissibility of atypical prions from genetic CJD(G114V)
por: Cali, Ignazio, et al.
Publicado: (2018)

Clarinet trio, op. 114 ; Clarinet quintet, op. 115
por: Brahms, Johannes, 1833-1897
Publicado: (1993)

P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults
por: Platt, Heather, et al.
Publicado: (2023)

Signals for the CPS 114 MHz RF system
por: Croizat, M, et al.
Publicado: (1986)

A ferrite tuner for the 114 MHz cavity
por: Hohbach, R, et al.
Publicado: (1988)

ALPHA User's Guide (Version 114/115)
por: Blucher, E, et al.
Publicado: (1992)

The shell model parameters of the Z = 114 region
por: Gustafsson, C
Publicado: (1970)

Cannot write session to /tmp/vufind_sessions/sess_brmjbn11hhk59s7qcptqgsp9v4